ThesisBiogen: the story is balanced — Leqembi commercial uptake metrics - quarterly patient starts, reimbursement coverage decisions…
★ Analysts see FY2026 revenue reaching $10.5B — +9.6% growth in a single year.
What Moves the Stock
- 01Leqembi commercial uptake metrics - quarterly patient starts, reimbursement coverage decisions, and market share versus competing amyloid therapies
- 02MS franchise erosion rate - Tecfidera biosimilar penetration in Europe and US, Tysabri patient retention amid safety concerns
- 03Pipeline readouts - Phase 2/3 data for neuropsychiatry assets (depression, schizophrenia programs), ALS candidates, and rare disease programs
- 04Capital allocation announcements - share buyback authorizations, dividend policy, and M&A activity to supplement organic pipeline
- 05Regulatory developments - FDA/EMA decisions on Alzheimer's disease diagnostic requirements, safety label updates for legacy products
- 06Multiple Sclerosis franchise (Tecfidera, Tysabri, Vumerity) - estimated 45-50% of revenue, facing biosimilar competition
- 07Spinal Muscular Atrophy (Spinraza) - estimated 20-25% of revenue, competing with gene therapies
- 08Biosimilars and contract manufacturing (Samsung Bioepis partnership) - estimated 10-15% of revenue
My Notes
- value - The stock trades at 2.9x price/sales and 10.5x EV/EBITDA, below historical biotech averages…
- Rising interest rates create moderate headwinds through two channels: (1) higher discount rates compress NPV of long-duration pipeline…
- Watch on earnings: Leqembi quarterly patient enrollment and annualized revenue run-rate (Eisai reports), Tecfidera US prescription trends and biosimilar market share (IQVIA weekly data), Spinraza global patient numbers and competitive gene therapy penetration rates.
One Sentence Summary:
Biogen: the story is balanced — leqembi commercial uptake metrics - quarterly patient starts, reimbursement coverage decisions.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
